100 Overlook Center
Suite 102
Princeton, NJ 08540
United States
609 375 2227
https://www.sonnetbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 12
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Pankaj Mohan Ph.D. | Founder, Chairman, CEO & President | 927k | N/A | 1965 |
Dr. John K. Cini Ph.D. | Chief Scientific Officer & Co-Founder | 602.48k | N/A | 1953 |
Mr. Jay Cross | Chief Financial Officer | 603.42k | N/A | 1970 |
Mr. Donald J. Griffith CPA, CPA | Controller & Director | 134.05k | N/A | 1949 |
Ms. Susan Dexter | Chief Technical Officer | N/A | N/A | 1955 |
Dr. Richard T. Kenney FACP, M.D. | Chief Medical Officer | N/A | N/A | 1958 |
Mr. Manuel Dafonseca | Head of Clinical Operations | N/A | N/A | N/A |
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Sonnet BioTherapeutics Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.